Observational Study of Health Utilities in Adult Primary Ciliary Dyskinesia Patients: Preliminary Data on Associations with Molecular Diagnosis, Clinical Phenotype and HRQOL Measures

Overview

Journal Multidiscip Respir Med

Specialty Pulmonary Medicine

Date 2023 Jan 13

PMID 36636646

Authors

Panayiotis Kouis

Maria G Kakkoura

Stavria Artemis Elia

Phivos Ioannou

Pinelopi Anagnostopoulou

Louiza Potamiti

Maria A Loizidou

Mihalis I Panayiotidis

Kyriacos Kyriacou

Andreas Hadjisavvas

Panayiotis K Yiallouros

Affiliations

Soon will be listed here.

Abstract

Background: Primary ciliary dyskinesia (PCD) is a congenital disorder characterized by chronic respiratory morbidity. To date, there is no information on PCD-specific preference-based quality of life measures such as health utilities (HU). We cross-sectionally assessed HU in adult PCD patients and explored relationships with genotype, phenotype and quality of life (QOL)-PCD scales.

Methods: Diagnostic testing was performed according to international guidelines, while participants completed the visual analog scale (VAS), time trade off (TTO), standard gamble (SG), and EuroQol 5 dimensions (EQ5D) HU instruments, as well as the QOL-PCD questionnaire. Hierarchical regression was used to identify the QOL-PCD scales that are most predictive of HU.

Results: Among 31 patients, median HU are 0.75 (VAS), 0.86 (EQ5D), 0.91 (TTO) and 0.99 (SG). The underlying genotype is not associated with HU measures. VAS and EQ5D are associated with lung function, while TTO and SG values are not sensitive to any of the examined factors. Among the QOL-PCD scales, physical functioning and lower respiratory symptoms explained much of VAS (R= 0.419) and EQ5D (R= 0.538) variability.

Conclusions: Our study demonstrates that HU elicitation in PCD is feasible using both direct and indirect methods. Overall, HU scores are relatively high among adult patients, with higher scores observed in SG and TTO, followed by EQ5D and VAS. VAS and EQ5D HU values are sensitive to lung function as well as to QOL-PCD physical functioning and lower respiratory symptom scores.

References

Neumann P, Thorat T, Shi J, Saret C, Cohen J . The changing face of the cost-utility literature, 1990-2012. Value Health. 2015; 18(2):271-7. DOI: 10.1016/j.jval.2014.12.002. View

Behan L, Leigh M, Dell S, Galvin A, Quittner A, Lucas J . Validation of a health-related quality of life instrument for primary ciliary dyskinesia (QOL-PCD). Thorax. 2017; 72(9):832-839. PMC: 5738537. DOI: 10.1136/thoraxjnl-2016-209356. View

Kontodimopoulos N, Niakas D . Overcoming inherent problems of preference-based techniques for measuring health benefits: an empirical study in the context of kidney transplantation. BMC Health Serv Res. 2006; 6:3. PMC: 1373617. DOI: 10.1186/1472-6963-6-3. View

Grutters J, Joore M, van der Horst F, Verschuure H, Dreschler W, Anteunis L . Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints. Qual Life Res. 2007; 16(8):1439-49. PMC: 2039846. DOI: 10.1007/s11136-007-9237-x. View

McManus I, Stubbings G, Martin N . Stigmatization, physical illness and mental health in primary ciliary dyskinesia. J Health Psychol. 2006; 11(3):467-82. DOI: 10.1177/1359105306063320. View

Cohen-Cymberknoh M, Simanovsky N, Hiller N, Hillel A, Shoseyov D, Kerem E . Differences in disease expression between primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency. Chest. 2013; 145(4):738-744. DOI: 10.1378/chest.13-1162. View

Lucas J, Barbato A, Collins S, Goutaki M, Behan L, Caudri D . European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J. 2016; 49(1). PMC: 6054534. DOI: 10.1183/13993003.01090-2016. View

Kouis P, Hadjisavvas A, Middleton N, Papatheodorou S, Kyriacou K, Yiallouros P . The effect of l-Arginine on Ciliary Beat Frequency in PCD patients, non-PCD respiratory patients and healthy controls. Pulm Pharmacol Ther. 2017; 48:15-21. DOI: 10.1016/j.pupt.2017.10.010. View

Dettmer S, Ringshausen F, Vogel-Claussen J, Fuge J, Faschkami A, Shin H . Computed tomography in adult patients with primary ciliary dyskinesia: Typical imaging findings. PLoS One. 2018; 13(2):e0191457. PMC: 5800555. DOI: 10.1371/journal.pone.0191457. View

10.

Pifferi M, Bush A, Mule G, Gracci S, Fonnesu R, Michelucci A . Longitudinal Lung Volume Changes by Ultrastructure and Genotype in Primary Ciliary Dyskinesia. Ann Am Thorac Soc. 2021; 18(6):963-970. DOI: 10.1513/AnnalsATS.202007-816OC. View

11.

Knowles M, Ostrowski L, Leigh M, Sears P, Davis S, Wolf W . Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. Am J Respir Crit Care Med. 2014; 189(6):707-17. PMC: 3983840. DOI: 10.1164/rccm.201311-2047OC. View

12.

Salaffi F, Stancati A, Carotti M . Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis. Clin Rheumatol. 2002; 21(6):478-87. DOI: 10.1007/s100670200119. View

13.

Ioannou P, Kouis P, Kakkoura M, Kaliva M, Toliopoulou A, Andreou K . Health related quality of life in adult primary Ciliary dyskinesia patients in Cyprus: development and validation of the Greek version of the QOL-PCD questionnaire. Health Qual Life Outcomes. 2020; 18(1):105. PMC: 7178983. DOI: 10.1186/s12955-020-01360-w. View

14.

Yiallouros P, Kouis P, Pirpa P, Michailidou K, Loizidou M, Potamiti L . Wide phenotypic variability in RSPH9-associated primary ciliary dyskinesia: review of a case-series from Cyprus. J Thorac Dis. 2019; 11(5):2067-2075. PMC: 6588774. DOI: 10.21037/jtd.2019.04.71. View

15.

Brundage M, Bass B, Davidson J, Queenan J, Bezjak A, Ringash J . Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. Qual Life Res. 2010; 20(5):653-64. DOI: 10.1007/s11136-010-9793-3. View

16.

Emiralioglu N, Taskiran E, Kosukcu C, Bilgic E, Atilla P, Kaya B . Genotype and phenotype evaluation of patients with primary ciliary dyskinesia: First results from Turkey. Pediatr Pulmonol. 2019; 55(2):383-393. DOI: 10.1002/ppul.24583. View

17.

Attema A, Edelaar-Peeters Y, M Versteegh M, Stolk E . Time trade-off: one methodology, different methods. Eur J Health Econ. 2013; 14 Suppl 1:S53-64. PMC: 3728453. DOI: 10.1007/s10198-013-0508-x. View

18.

McManus I, Mitchison H, Chung E, Stubbings G, Martin N . Primary ciliary dyskinesia (Siewert's/Kartagener's syndrome): respiratory symptoms and psycho-social impact. BMC Pulm Med. 2003; 3:4. PMC: 317322. DOI: 10.1186/1471-2466-3-4. View

19.

Bradley J, Blume S, Balp M, Honeybourne D, Elborn J . Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J. 2012; 41(3):571-7. DOI: 10.1183/09031936.00224911. View

20.

Hogg K, Shaw J, Coyle D, Fallah P, Carrier M, Wells P . Validity of standard gamble estimated quality of life in acute venous thrombosis. Thromb Res. 2014; 134(4):819-25. DOI: 10.1016/j.thromres.2014.07.029. View